84 related articles for article (PubMed ID: 23591843)
21. Pigment Epithelium-Derived Factor as a Possible Treatment Agent for Choroidal Neovascularization.
Xi L
Oxid Med Cell Longev; 2020; 2020():8941057. PubMed ID: 32215180
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a rat corneal experimental angiogenesis model.
Kuo CN; Chen CY; Chen SN; Yang LC; Lai LJ; Lai CH; Chen MF; Hung CH; Chen CH
Int J Mol Sci; 2013 Apr; 14(4):8291-305. PubMed ID: 23591843
[TBL] [Abstract][Full Text] [Related]
23. Anti-angiogenic effect of hexahydrocurcumin in rat corneal neovascularization.
Kuo CN; Chen CH; Chen SN; Huang JC; Lai LJ; Lai CH; Hung CH; Lee CH; Chen CY
Int Ophthalmol; 2018 Apr; 38(2):747-756. PubMed ID: 28393322
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Topical Pigment Epithelium-Derived Factor (PEDF) with Topical Bevacizumab for Accelerating the Regression of Corneal Neovascularization in an Experimental Model of Rabbit Corneal Angiogenesis.
Mahmoudzadeh R; Heidari-Keshel S; Mehrpour M; Asadi Amoli F; Aghajanpour L; Lashay A
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1471-1477. PubMed ID: 32407187
[No Abstract] [Full Text] [Related]
25. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).
Azar DT
Trans Am Ophthalmol Soc; 2006; 104():264-302. PubMed ID: 17471348
[TBL] [Abstract][Full Text] [Related]
26. PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression.
Matsui T; Nishino Y; Maeda S; Yamagishi S
Microvasc Res; 2012 Jul; 84(1):105-8. PubMed ID: 22386653
[TBL] [Abstract][Full Text] [Related]
27. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo.
Mohan RR; Tovey JC; Sharma A; Schultz GS; Cowden JW; Tandon A
PLoS One; 2011; 6(10):e26432. PubMed ID: 22039486
[TBL] [Abstract][Full Text] [Related]
28. Anti-angiogenic and anti-inflammatory effects of SERPINA3K on corneal injury.
Liu X; Lin Z; Zhou T; Zong R; He H; Liu Z; Ma JX; Liu Z; Zhou Y
PLoS One; 2011 Jan; 6(1):e16712. PubMed ID: 21304961
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis.
Kuo CN; Yang LC; Yang CT; Lai CH; Chen MF; Chen CY; Chen CH; Wu PC; Kou HK; Chen YJ; Hung CH; Tsai CB
Exp Eye Res; 2009 Nov; 89(5):678-85. PubMed ID: 19596319
[TBL] [Abstract][Full Text] [Related]
30. Suppression of Sproutys has a therapeutic effect for a mouse model of ischemia by enhancing angiogenesis.
Taniguchi K; Sasaki K; Watari K; Yasukawa H; Imaizumi T; Ayada T; Okamoto F; Ishizaki T; Kato R; Kohno R; Kimura H; Sato Y; Ono M; Yonemitsu Y; Yoshimura A
PLoS One; 2009; 4(5):e5467. PubMed ID: 19424491
[TBL] [Abstract][Full Text] [Related]
31. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
[TBL] [Abstract][Full Text] [Related]
32. A novel vector system for gene transfer into the cornea using a partially dried plasmid expressing 18 basic fibroblast growth factor-synthetic amphiphile INTeraction-18 (SAINT-18) complex.
Kuo CN; Yang LC; Yang CT; Chen MF; Lai CH; Chen YH; Chen CH; Chen CH; Wu PC; Kou HK; Tsai JC; Hung CH
Curr Eye Res; 2008 Oct; 33(10):839-48. PubMed ID: 18853317
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor mediates corneal nerve repair.
Yu CQ; Zhang M; Matis KI; Kim C; Rosenblatt MI
Invest Ophthalmol Vis Sci; 2008 Sep; 49(9):3870-8. PubMed ID: 18487369
[TBL] [Abstract][Full Text] [Related]
34. The effect of topical bevacizumab on corneal neovascularization.
Kim SW; Ha BJ; Kim EK; Tchah H; Kim TI
Ophthalmology; 2008 Jun; 115(6):e33-8. PubMed ID: 18439681
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
37. Modeling of corneal and retinal pharmacokinetics after periocular drug administration.
Amrite AC; Edelhauser HF; Kompella UB
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):320-32. PubMed ID: 18172109
[TBL] [Abstract][Full Text] [Related]
38. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
